NIDA's clinical trials network: An opportunity for HIV research in community substance abuse treatment programs

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 283-293

  Tross, Susan ^a   Campbell, Aimee N C ^a   Calsyn, Donald A ^b   Metsch, Lisa R ^c   Sorensen, James L ^d   Shoptaw, Steven ^e   Haynes, Louise ^f   Woody, George E ^g   Malow, Robert M ^h   Brown Jr , Lawrence S ⁱ   Feaster, Daniel J ^c   Booth, Robert E ^j   Mandler, Raul N ^k   Masson, Carmen ^d   Holmes, Beverly W ^f   Colfax, Grant ^l   Brooks, Audrey J ^m   Hien, Denise A ⁿ   Schackman, Bruce R ^o   Korthuis, P Todd ^p   Miele, Gloria M ^a   more..

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h FLORIDA INTERNATIONAL UNIVERSITY   (United States)

ⁱ Addiction Research and Treatment Corporation   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^l SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^m The University of Arizona   (United States)

ⁿ CITY UNIVERSITY OF NEW YORK   (United States)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Clinical Trials Network; Effectiveness research; HIV AIDS; Substance abuse

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COUNSELING; CRISIS INTERVENTION; DRUG DEPENDENCE TREATMENT; DRUG USE; HEALTH EDUCATION; HEALTH SERVICE; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATIONAL HEALTH ORGANIZATION; RESEARCH; RISK ASSESSMENT; RISK REDUCTION; SAFE SEX; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

CLINICAL TRIALS AS TOPIC; COMMUNITY HEALTH SERVICES; COOPERATIVE BEHAVIOR; HIV INFECTIONS; HUMANS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); RESEARCH DESIGN; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 80052195495     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596977     Document Type: Article

References (84)

1. Hanson GR, Leshner AI, Tai B. Putting drug research to use in real-life settings. J Subst Abuse Treat 2002; 23(2):69-70. (Pubitemid 36151687)
2. Institute of Medicine. Bridging the Gap between Practice and Research. Washington, DC: National Academy Press, 1998
3. Tai B, Straus MM, Liu D, Sparenborg S, Jackson R, McCarty D. The first decade of the National Drug Abuse Treatment Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. J Subst Abuse Treat 2010; 38(S1):S4-S13.
4. Center for Disease Control and Prevention. HIV prevalence estimates - United States 2006. MMWR 2006; 57(39): 1073-1076.
5. Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four U.S. cities. J Urban Health 2001; 78:152-161. (Pubitemid 32429059)
6. Sorensen JL, Masson CL, Perlman DC. HIV/hepatitis prevention in substance abuse treatment programs: Guidance from research. NIDA Sci Pract Perspect 2002; 1:4-11.
7. Tempalski B, Cooper HL, Friedman SR, Des Jarlais DC, Brady J, Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy 2008; 19:S47-S58.
8. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy 2005; 16:S31-S44. (Pubitemid 41735173)
9. Booth RE, Kwaitkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoactive Drugs 1998; 30(3):269-278. (Pubitemid 28467633)
10. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: The first 25 years and counting. Psychosom Med 2008; 70:606-611.
11. Metzger D, Navaline H, Woody G. Drug abuse treatment is AIDS prevention. Public Health Rep 1998; 113(S1): 97-106. (Pubitemid 29330151)
12. Sorensen J, Copeland A. Drug abuse treatment as an AIDS prevention strategy: A review. Drug Alcohol Depend 2000; 59:17-31. (Pubitemid 30116835)
13. Metzger DS, Woody GE, OBrien CP. Drug treatment as HIV prevention: A research update. J Acquir Immune Defic Syndr 2010; 55:S32-S36.
14. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; 2:CD004145.
15. Colfax G, Shoptaw S. Themethamphetamine epidemic: Implications for HIV prevention and treatment. Current HIV/AIDS Rep 2005; 2(4):194-199.
16. Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatry 2007; 164:157-160. (Pubitemid 46154796)
17. Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddermann A, Kumar S, Hart C. Amphetamine-group substances and HIV. Lancet 2010; 376(9739):458-474.
18. Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Abdul-Quader A, Heckathorn DD, McKnight C, Bramson H, Nemeth C, Torian LV, Friedman SR. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007; 21(2):231-235. (Pubitemid 46036932)
19. PrendergastM, Urada D, Podus D. Meta-analysis of HIV riskreduction interventions within drug abuse treatment programs. J Consult Clin Psychol 2001; 69:389-405. (Pubitemid 32667022)
20. Semaan S, Des Jarlais D, Sogolow E, Johnson WD, Hedges LV, Ramirez G, Flores SA, Norman L, Sweat MD, Needle R. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr 2002; 30:S73-S93. (Pubitemid 34774067)
21. Copenhaver M, Johnson B, Lee I, Harman J, Carey M, the SHARP Research Team. Behavioral HIV risk reduction among people who inject drugs: Meta-analytic evidence of efficacy. J Subst Abuse Treat 2006; 31:163-171. (Pubitemid 44223907)
22. Meader N, Li R, Des Jarlais DC, Pilling S. Psychosocial interventions for reducing injection and sexual risk behavior for preventing HIV in drug users. Cochrane Database Syst Rev 2010; 1:CD007192.
23. Exner T, Seal D, Ehrhardt A. A review of HIV interventions for at-risk women. AIDS Behav 1997; 2:93-124. (Pubitemid 127716742)
24. Shoptaw S, Tross S, Stephens M, Tai B, the NIDA CTN HIV/AIDS Workgroup. A snapshot of HIV/AIDS-related services in the clinical treatment providers for NIDAs Clinical Trials Network. Drug Alcohol Depend 2002; 66:S163.
25. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. J Am Med Assoc 2009; 301(22):2380-2382.
26. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009; 373(9657):48-57.
27. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368(9534):531-536. (Pubitemid 44142776)
28. Volkow ND, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. J Am Med Assoc 2010; 303(14):1423-1424.
29. Lambert EY, Normand JL, Volkow ND. Prevention and treatment of HIV/AIDS among drug-using populations: A global perspective. J Acquir Immune Defic Syndr 2010; 55: S1-4.
30. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE, Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006; 55(RR-14):1-17.
31. Brown LS Jr, Kritz SA, Goldsmith RJ, Bini EJ, Rotrosen J, Baker S, Robinson J, McAuliffe P. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: The national drug abuse treatment Clinical Trials Network. J Subst Abuse Treat 2006; 30(4): 315-321. (Pubitemid 44255783)
32. Oser CB, Tindall MS, Leukefeld CG. HIV testing in correctional agencies and community treatment programs: The impact of internal organizational structure. J Subst Abuse Treat 2007; 32(3):301-310. (Pubitemid 46441717)
33. Strauss SM, Des Jarlais DC, Astone J, Vassilev ZP. On-site HIV testing in residential drug treatment units: Results of a nationwide survey. Pub Health Rep 2003; 118(1):37-43. (Pubitemid 36262461)
34. Pollack HA, DAunno T. HIV testing and counseling in the nations outpatient substance abuse treatment system, 1995- 2005. J Subst Abuse Treat 2010; 38(4):307-316.
35. Center for Disease Control and Prevention. Late HIV Testing - 34 states, 1996-2005. MMWR 2009, 58:24,661-665.
36. Metsch LR, Bell C, Pereyra M, Cardenas G, Sullivan T, Rodriguez A, Gooden L, Khoury N, Kuper T, Brewer T, del Rio C. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Pub Health 2009; 99(6):1045-1049.
37. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, SteinMD, Longshore D, Bozzette SA. Effects of drug abuse andmental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med 2001; 16(9):639-641.
38. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17: 377-381. (Pubitemid 34626108)
39. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131(2):81-87. (Pubitemid 29340558)
40. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci 2011; 88(21-22):948-952.
41. Mugavero M, Ostermann J, Whetten K, Leserman J, Swartz M, Stangl D, Thielman N. Barriers to antiretroviral adherence: The importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS 2006; 20(6): 418-428. (Pubitemid 43993096)
42. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. J Am Med Assoc 2008; 300(5):550-554.
43. Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD. Clinic-based treatment of opioiddependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann InternMed 2010; 152(11):704-711.
44. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, PantalonMV, OConnor PG, Schottenfeld RS, Fiellin DA. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43(S4):S184-90. (Pubitemid 44901886)
45. Haynes LF, Calsyn DA, Tross S. Addressing sexual issues in addictions treatment. Counselor 2008; 9(4):28-36.
46. National Institute on Drug Abuse. Risk Behavior Survey (3rd ed). Rockville, MD: Community Research Branch, National Institute on Drug Abuse, 1993.
47. Wexler HK, Fletcher BW. National Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) overview. Prison J 2007; 87(1):9-24.
48. Brown LS, Kritz SA, Goldsmith RJ, Bini EJ, Robinson J, Alderson D, Rotrosen J. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep 2007; 122: 441-451.
49. Kritz SA, Brown LS, Goldsmith RJ, Bini EJ, Robinson J, Alderson D, Novo P, Rotrosen J. States and substance abuse treatment programs: Funding and guidelines for infectionrelated services. Am J Public Health 2008; 98:824-826. (Pubitemid 351671573)
50. Brown LS, Kritz SA, Muhammad A, Bini EJ, Goldsmith RJ, Robinson J, Alderson D, Hasin DS, Rotrosen J. Disparities in health services for HIVAIDS, hepatitis C virus, and sexually transmitted infections: Role of substance abuse treatment programs. J Addict Med 2009; 3:95-102.
51. Carroll KM, Rosa C, Brown LS, Daw R, Magruder KM, Beatty L. Addressing ethnic disparities in drug abuse treatment in the Clinical Trials Network. J Subst Abuse Treat 2007; 90:101-106.
52. Coyle SL. The NIDA HIV Counseling and Education InterventionModel: InterventionManual. Rockville,MD: National Institute on Drug Abuse, 1993.
53. Stark MJ, Kane BJ. General and specific psychotherapy role induction with substance-abusing clients. Int J Addict 1985; 20(8):1135-1141. (Pubitemid 16213144)
54. Campbell BK, Fuller BE, Lee ES, Tillotson C, Woelfel T, Jenkins L, Robinson J, Booth RE, McCarty D. Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions. Psychol Addict Behav 2009; 23:260-270.
55. Booth RE, Campbell BK, Mikulich-Gilbertson SK, Tillotson CJ, Choi D, Robinson J, Calsyn DA, Mandler RN, Jenkins LM, Thompson LL, Dempsey CL, Liepman MR, McCarty D. Reducing HIV-related risk behaviors among injection drug users in residential detoxification. AIDS Behav 2011; 15(1): 30-44.
56. Logan TK, Cole J, Leukefeld C.Women, sex, and HIV: Social and contextual factors, meta-analysis of published interventions, and implications for practice and research. Psychol Bull 2002; 128(6):851-885.
57. The NIMH Multisite HIV Prevention Trial Group. The NIMH Multisite HIV Prevention Trial: Reducing HIV sexual behavior risk. Science 1998; 280:1889-1894.
58. Bartholomew NG, Simpson DD. Time Out! ForMen: A Communication Skills and Sexuality Workshop for Men. Fort Worth, TX: Institute for Behavioral Research, Texas Christian University, 1996.
59. Calsyn DA,Wells EA, Saxon AJ, Jackson R, Heiman JR. Sexual activity under the influence of drugs is common among methadone clients. In Problems of Drug Dependence 1999. LS Harris, ed. Rockville, MD: National Institute on Drug Abuse, 2000; NIH Pub. No. 00-4773; 315.
60. Calsyn DA, Crits-Christoph P, Hatch-Maillette M, Doyle SR, Song YS, Coyer S, Pelta S. Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment. Addiction 2010; 105:100-108.
61. Calsyn DA, Hatch-Maillette M, Tross S, Doyle SR, Crits- Christoph P, Song YS, Harrer JM, Lalos G, Berns SB.Motivational and skills training HIV/STI sexual risk reduction groups for men. J Subst Abuse Treat 2009; 37(2):138-150.
62. El-Bassel N, Schilling R. 15-Month follow-up of women methadone patients taught skills to reduce heterosexual HIV transmission. Public Health Rep 1992; 107:500-504.
63. Schilling R, El-Bassel N, Schinke S, Gordon K, Nichols S. Building skills of recovering women drug users to reduce heterosexual AIDS transmission. Public Health Rep 1991; 106(3):297-304.
64. Tross S, Campbell ANC, Cohen LR, Calsyn D, Pavlicova M, Miele GM, Hu MC, Haynes L, Nugent N, Gan W, Hatch-Maillette M, Mandler R, McLaughlin P, El-Bassel N, Crits-Christoph P, Nunes EV. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: Results of a NIDA Clinical Trials Network trial. J Acquir Immune Defic Syndr 2008; 48(5): 581-589.
65. Metsch LR. HIV Testing in Drug Abuse Treatment: New Paradigms. Presentation at the NIDA Blending Conference, Cincinnati, OH, June, 2008.
66. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, Zenilman J, Hoxworth T, Malotte CK, Iatesta M, Kent C, Lentz A, Graziano S, Byers RH, Peterman TA. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial. J Am Med Assoc 1998; 280: 1161-1167. (Pubitemid 28457806)
67. Metcalf CA, Douglas JM Jr,Malotte CK, Cross H, Dillon BA, Paul SM, Padilla SM, Brookes LC, Lindsey CA, Byers RH, Peterman TA, the RESPECT-2 Study Group. Relative efficacy of prevention counseling with rapid and standard HIV testing: A randomized controlled trial (RESPECT-2). Sex Transm Dis 2005; 32(2):130-138.
68. Schackman B. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs. Available at Research Portfolio Online Reporting Tools http://projectreporter.nih.gov. Last accessed on August 31, 2010.
69. Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell ANC, Cohen LR, Miele GM, Killeen T, Brigham GS, Zhang Y, Hansen C, Hodgkins C, Hatch-Maillette M, Brown C, Kulaga A, Kristman-Valente A, Chu M, Sage R, Robinson JA, Liu D, Nunes EV. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders: Primary outcomes from the NIDA Clinical Trials Network "Women and Trauma" multisite randomized control trial. J Consult Clin Psychol 2009; 77(4):607-619.
70. Najavits LM. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. New York, NY: Guilford Press, 2002.
71. Hien DA, Campbell ANC, Killeen T, Hu M, Hansen C, Jiang H, Hatch-Maillette M, Miele GM, Cohen LR, Gan W, Resko SM, DiBono M, Wells EA, Nunes EV. The impact of trauma-focused group therapy upon HIV risk behaviors in the NIDA Clinical Trials Network "Women and Trauma" multi-site study. AIDS Behav 2010; 14(2): 421-430.
72. Hopfer CJ, Mikulich SK, Crowley TJ. Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000; 39(10):1316-1323.
73. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. J Am Med Assoc 2008; 300(17):2003-2011.
74. Brooks AJ, Meade CS, Potter JS, Lokhnygina Y, Calsyn DA, Greenfield SF. Gender differences in rates and correlates of HIV risk behaviors among drug dependent individuals. Subst Use Misuse 2010; 45(14):2444-2469.
75. Sorensen JL. Directly Administered Antiretroviral Therapy (DAART+) as a Structural HIV Intervention in Methadone Maintenance. Available at Research Portfolio Online Reporting Tools http://projectreporter.nih.gov. Last accessed on August 31, 2010.
76. Masson CM. Hepatitis Care Coordination in Methadone Treatment. Available at Research Portfolio Online Reporting Tools http://projectreporter.nih.gov. Last accessed on August 31, 2010.
77. Perlman D. HIV and Hepatitis Care Coordination in Methadone Treatment. Available at Research Portfolio Online Reporting Tools http://projectreporter. nih.gov. Last accessed on August 31, 2010.
78. Calsyn DA. Computerized Assistance for Treatment Professionals in Assessment of Sexual Risk, 2008. Available at Research Portfolio Online Reporting Tools http://projectreporter.nih.gov. Last accessed on August 31, 2010.
79. Svikis D. Reducing HIV: Safer Sex Skill Building in Pregnant, Drug-Abusing Women/Virginia Commonwealth University NIH P60 Health Disparities Center. Available at Research Portfolio Online Reporting Tools http://projectreporter.nih.gov. Last accessed on August 31, 2010.
80. Gordon S. Targeted Capacity Expansion Program for Substance Abuse Treatment and HIV/AIDS Services. Seabrook, NJ: Seabrook House, 2008.
81. Campbell ANC, Hartzler B, Hatch-Maillette M, Calsyn DA, Miele GM, Tross S. Community providers impression of HIV prevention intervention research within NIDAs. Clinical Trials Network J Drug Issues (in press).
82. Sterling RC Barriers to Using the Real Men Are Safe Protocol in Methadone Maintenance Programs. Presentation at the Annual Meeting of the American Association for the Treatment of Opioid Dependence, Chicago. IL, October 27, 2010.
83. Guydish J, Tajima B, Manser S, Jessup M. Strategies to encourage adoption in multi-site clinical trials. J Subst Abuse Treat 2007; 32:177-188. (Pubitemid 46240722)
84. Marsch LA, Bickel WK. Efficacy of computer-based HIV/AIDS education for injection drug users. Am J Health Behav 2004; 28(4):316-327. (Pubitemid 39178429)